Drugs That Distort Polysomnography (Sleep Study) Results

What Polysomnography Measures and Why Drug Effects Matter

Polysomnography records at least 12 simultaneous physiological signals during sleep: electroencephalography (EEG) for sleep staging, electrooculography (EOG) for eye movements, submental and tibial electromyography (EMG), nasal pressure and thermistor airflow, thoracic and abdominal respiratory effort belts, pulse oximetry, electrocardiography (ECG), body position, and a snoring microphone. The test produces a scored hypnogram that maps sleep stages across the night and calculates the Apnea-Hypopnea Index (AHI), the primary metric used to diagnose OSA [1].

How Sleep Architecture Shapes the Diagnosis

Any substance that shifts the proportion of N1, N2, N3, or REM sleep changes the backdrop against which respiratory events are counted. REM sleep is when upper-airway collapsibility tends to be greatest because of muscle atonia [2]. A drug that reduces or eliminates REM sleep removes much of the window in which obstructive events are most likely to occur, which can produce an artificially low AHI that understates true disease severity.

Why Clinicians Need an Unmedicated Baseline

The American Academy of Sleep Medicine (AASM) recommends that, whenever clinically safe, medications known to affect sleep architecture or respiratory drive be held before diagnostic PSG [3]. The goal is to capture the patient's intrinsic sleep-breathing pattern. When a drug cannot be safely discontinued, such as chronic opioid therapy or an anti-seizure regimen, the interpreting physician needs that information to interpret the study correctly rather than expecting the patient to stop the drug.

Benzodiazepines and Non-Benzodiazepine Receptor Agonists

Benzodiazepines (diazepam, lorazepam, clonazepam) and "Z-drugs" (zolpidem, zaleplon, eszopiclone) bind GABA-A receptors, increase N2 spindle activity, suppress N3 slow-wave sleep, and can reduce REM proportion. A review of hypnotic drugs and polysomnography summarizes these effects across multiple agents and doses [4].

Impact on Respiratory Parameters

A study of zolpidem in patients with sleep apnea found that the drug blunted the brain's arousal response to respiratory events without eliminating the underlying airway obstruction [5]. In practice, this means a patient can keep obstructing just as often while the scored arousal index, and sometimes the AHI itself, looks better than it should, because hypopneas that no longer trigger a scoreable arousal get reclassified or missed. The oxygen desaturation index (ODI), which does not depend on arousals, is often a more reliable signal in a sedated patient than the AHI alone.

Impact on Muscle Tone Recordings

Clonazepam is commonly prescribed for REM behavior disorder (RBD). If a patient takes clonazepam the night of a diagnostic PSG intended to confirm RBD, the drug can suppress the phasic chin and limb EMG bursts the study is designed to detect, potentially masking the diagnosis. The general principle that sedating medications should be held before diagnostic PSG when safe [3] applies here: tapering clonazepam before an RBD-diagnostic study, with the prescriber's agreement, gives a clearer picture.

Hold Guidance

Zolpidem has a half-life of roughly 2.5 hours, so it largely clears the body in about 12 hours. Diazepam's half-life of 20 to 100 hours, extended further by active metabolites, can require 5 or more days, sometimes weeks, to clear. Any hold plan should be set with the prescribing clinician, not decided unilaterally.

Opioids and Respiratory Drive

Opioids are among the most clinically significant PSG confounders. Mu-receptor agonists (morphine, oxycodone, hydrocodone, methadone, fentanyl) depress medullary chemoreceptor sensitivity, which can produce central apneas and ataxic (Biot) breathing patterns that reflect the drug's effect on respiratory drive rather than the patient's airway anatomy [6].

Central vs. Obstructive Patterns

A study of chronic opioid users (N=60) reported that about 75% had some form of sleep-disordered breathing, split roughly between central sleep apnea, ataxic breathing, and obstructive events, with higher morphine-equivalent daily doses associated with more severe breathing abnormalities [7]. Methadone, with its long and variable half-life (roughly 8 to 59 hours), is particularly difficult to work around. Stopping chronic opioid therapy before a sleep study is rarely safe or appropriate, so the interpreting physician generally has to read the study knowing that observed central events may be partly opioid-driven and could change if the opioid regimen changes.

Why This Matters for Pain Patients

A PSG performed on a patient taking a substantial daily opioid dose may show a mixed apnea pattern. CPAP has strong evidence behind it for reducing obstructive events specifically [22], but it does not treat a central component caused by opioids. Adaptive servo-ventilation (ASV) is sometimes used for opioid-related central apnea, but ASV has its own contraindications, notably in some patients with reduced heart-pump function. Whether the opioid context is disclosed and documented can change the entire treatment pathway that follows the study.

SSRIs, SNRIs, and REM-Sleep Suppression

Selective serotonin reuptake inhibitors (fluoxetine, sertraline, paroxetine, escitalopram) and serotonin-norepinephrine reuptake inhibitors (venlafaxine, duloxetine) increase serotonergic tone, which tends to suppress REM sleep onset and reduce total REM percentage, with the degree varying by dose and specific agent [8].

How REM Suppression Masks Apnea Severity

OSA is typically worst during REM sleep, when postural muscle atonia allows maximal pharyngeal collapse. A patient on a higher-dose SSRI may spend well below the normal 20-25% of total sleep time in REM. If the interpreting physician does not look specifically at the REM-stage AHI, the overall AHI can undercount the patient's true disease burden. The Endocrine Society's 2018 testosterone therapy guideline notes the importance of capturing adequate REM sleep for a reliable OSA assessment, which is relevant for men on SSRIs who are also being evaluated before starting testosterone therapy [9] (full guideline text also available at the Journal of Clinical Endocrinology & Metabolism [22]).

SSRI-Induced Bruxism and PLMs

SSRIs are also associated with increased periodic limb movements (PLMs) and bruxism during sleep. A systematic review of periodic limb movements during sleep in major depression found that antidepressant use, SSRIs among them, was associated with a higher PLM index [10]; the exact magnitude varies across studies and should not be treated as a fixed number for an individual patient. If the clinical question is whether a patient has restless legs syndrome or a periodic limb movement disorder, the SSRI needs to be factored into interpretation, or ideally held if that is safe.

Withdrawal Caution

Abruptly stopping an SSRI can cause REM rebound (vivid dreams, fragmented sleep, increased REM density) that equally distorts PSG in the opposite direction. A supervised taper over 2 to 4 weeks before the study is preferred when clinically appropriate, and should never be self-directed.

Stimulants: Amphetamines, Methylphenidate, Modafinil

CNS stimulants prescribed for ADHD or narcolepsy tend to suppress total sleep time, delay sleep onset, reduce sleep efficiency, and decrease REM and N3 percentages. Most of the controlled evidence for this comes from studies in children and adolescents with ADHD, but the pharmacology is consistent with effects seen in adults [11].

Effect on Multiple Sleep Latency Test (MSLT)

For narcolepsy evaluation, PSG is followed the next day by an MSLT, which measures how quickly a patient falls asleep and whether sleep-onset REM periods (SOREMPs) occur. Stimulants taken close to the MSLT can prevent SOREMPs from appearing, producing a false-negative result. AASM practice parameters for the MSLT and maintenance of wakefulness test call for a 2-week stimulant-free washout before testing whenever it can be done safely [12].

Modafinil and Armodafinil

Modafinil has a half-life of approximately 15 hours. It primarily reduces N3 sleep and appears to suppress REM less aggressively than amphetamines, but it can still delay sleep onset and lower sleep efficiency. A single dose taken the morning of the PSG night may not fully clear by lights-out.

Antihistamines and Over-the-Counter Sleep Aids

First-generation antihistamines (diphenhydramine, doxylamine, hydroxyzine) cross the blood-brain barrier, block H1 receptors, and produce sedation. They can increase total sleep time and reduce sleep latency, but they also tend to suppress REM sleep and increase N2 proportion [13].

The "Good Sleep" Illusion

Patients sometimes take diphenhydramine the night of a sleep study because they worry about not falling asleep in the lab. This well-intentioned choice can lower the arousal threshold and may reduce the scored AHI while true hypoxemia burden is unchanged or worse, because the brain mounts fewer protective arousals to end each event. Sleep labs generally instruct patients to avoid OTC sleep aids for at least 48 hours before PSG.

Second-Generation Antihistamines

Cetirizine and loratadine have minimal CNS penetration and, at standard doses, negligible effects on sleep architecture. These generally do not need to be held.

Cannabis (THC) and Cannabinoids

Delta-9-tetrahydrocannabinol (THC) tends to reduce REM sleep and shorten sleep latency, with variable effects on slow-wave sleep depending on dose, and can fragment sleep at higher doses [14]. Synthetic cannabinoids (dronabinol, nabilone) produce broadly similar EEG changes.

Emerging Data on THC and Apnea

A randomized trial of dronabinol for OSA (N=73) found a modest AHI reduction, on the order of roughly 10 events per hour, versus placebo at the higher studied dose [15]. That trial was investigating dronabinol as a potential therapy, but the same finding means a patient who uses THC regularly may present to the sleep lab with an artificially lower AHI. Stopping THC, in turn, can trigger REM rebound. A reasonable approach is to document actual use, keep the patient's usual pattern if stopping is impractical, and note the confound in the report.

Alpha-2 Agonists and Muscle Relaxants

Clonidine and tizanidine, both alpha-2 agonists, reduce sympathetic outflow, can lower the arousal threshold, and reduce REM sleep. Clonidine specifically has been linked to central apneas in some patients through its effect on ventilatory drive [16]. Baclofen and cyclobenzaprine deepen sedation and can reduce upper-airway muscle tone, potentially worsening obstructive events while also reducing the cortical arousals that would otherwise flag them.

Clinical Guidance

For patients on baclofen for spasticity, stopping it is dangerous because of withdrawal seizure risk. The sleep physician should annotate the PSG report and consider that the true AHI may run higher than the number that was scored.

Alcohol: The Overlooked Confounder

Alcohol is not a prescription drug, but it deserves mention because patients sometimes drink on study nights to help themselves sleep. Ethanol tends to suppress REM sleep in the first half of the night, trigger REM rebound in the second half, relax pharyngeal dilator muscles, and increase upper-airway resistance. A systematic review and meta-analysis of alcohol and sleep apnea risk found that even moderate intake meaningfully increased AHI on average compared with no alcohol, with the effect size varying across the pooled studies [17].

Pre-Study Instructions

Sleep labs should explicitly ask about alcohol use. A standard instruction is to avoid alcohol for at least 24 hours before the study.

Testosterone and GLP-1 Receptor Agonists: Context for HealthRX.com Patients

Exogenous Testosterone

The Endocrine Society's 2018 guideline recommends baseline sleep evaluation (PSG or home sleep apnea testing) before starting testosterone replacement therapy (TRT) in men with obesity or existing OSA symptoms, with re-evaluation 3 to 6 months after starting therapy [9]. Testosterone does not distort the PSG signal itself, but it can worsen OSA severity over time by promoting fat deposition around the airway and altering ventilatory sensitivity. A placebo-controlled trial in obese men with severe OSA (N=67, 18 weeks) found that testosterone therapy increased AHI on average compared with placebo [18]; exact effect sizes from a single small trial like this should be treated as directional rather than a number to apply to any individual patient.

GLP-1 Receptor Agonists and Weight Loss

Weight loss from semaglutide or tirzepatide can reduce AHI substantially. The SURMOUNT-OSA trial found that tirzepatide produced a considerably larger reduction in AHI at 52 weeks than placebo in participants not using PAP therapy [19]. Patients on GLP-1 therapy who undergo a repeat PSG may show improved AHI because of real weight-driven physiological change, not because the drug is interfering with the test itself. That distinction matters for how the result should be interpreted.

When to Repeat the Study

A PSG performed under heavy pharmacologic confounding may need to be repeated. Triggers for repeat testing include AHI results that are discordant with clinical symptoms (for example, severe daytime sleepiness with an AHI of 3), discovery after the study that a patient took an undisclosed sedative, a split-night study where insufficient REM was captured during the diagnostic half, and an MSLT that is negative in a clinically convincing narcolepsy presentation where stimulants were not adequately washed out. Coverage for repeat testing varies by payer and by how clearly the medication confound is documented; check the current CMS coverage determination for sleep testing and the specific plan's policy before assuming a repeat study will be covered [21].

A Medication Decision Framework for Your Sleep Study

Two questions drive almost every decision here: can this specific drug be stopped safely before this specific test, and does the diagnostic question the test is trying to answer actually depend on the drug's effect being absent. A stimulant washout matters enormously for an MSLT chasing narcolepsy and much less for a straightforward OSA screen. An opioid taper is rarely safe regardless of the diagnostic question. Use the table below as a starting point, then confirm the plan with the prescribing clinician and the sleep center.

If a medication is not on this table, the same two questions still apply: ask the prescriber whether stopping it is safe, and ask the sleep center whether the specific diagnostic question requires it to be absent. When in doubt, disclosing the medication and letting the interpreting physician account for it is safer than guessing at a hold schedule alone.